Form 4 for HOWL Werewolf Therapeutics, Inc.
Accepted 2025-04-30 00:00:00 ET · period of report 2025-03-27 · accession 0001415889-25-011569 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-04-30 | 2025-03-27 | HOWL | MPM ASSET MANAGEMENT LLC | 10% | S - Sale+OE | $1.05 | -4,386 | 6.72M | -0.1% | -$4,605 |
| DI | 2025-04-30 | 2025-03-27 | HOWL | MPM ASSET MANAGEMENT LLC | 10% | X - OptEx | $0.09 | +50.9K | 6.72M | +0.8% | +$4,579 |
| DMI | 2025-04-30 | 2025-03-27 | HOWL | MPM ASSET MANAGEMENT LLC | 10% | X - OptEx | $0.00 | -50.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-27 | S | D | 4,386 | $1.05 | 6,718,670 | I See Footnote | — | — | (F4) The shares are held as follows: 461,408 by AM LLC, 2,914,123 by BV 2014, 194,367 by BV 2014(B), 100,303 by AM BV2014, 639,659 by MPM OIF and 2,408,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| 2 | Common | Common Stock | 2025-03-27 | X | A | 50,873 | $0.09 | 6,723,056 | I See Footnote | — | — | (F2) The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,915,905 by MPM BioVentures 2014, L.P. ("BV 2014"), 194,486 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 100,365 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 640,121 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 2,410,771 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a member of AM LLC, a managing director of BV LLC and a manager of MPM OIF GP. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. (F3) MPM BioImpact LLC ("BioImpact") is the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing partner of BioImpact. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. |
| 3 | Derivative | Warrant (Right to Buy) | 2025-03-27 | X | D | 42,842 | $0.00 | 0 | I See Footnote | $0.09 · — to 2025-08-13 | 42,842 Common Stock | (F7) The warrants were held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV 2014, 5,355 by MPM OIF and 18,744 by UBS Oncology. (F5) Immediately exercisable. |
| 4 | Derivative | Warrant (Right to Buy) | 2025-03-27 | X | D | 8,031 | $0.00 | 0 | I See Footnote | $0.09 · — to 2025-04-09 | 8,031 Common Stock | (F6) The warrants were held as follows: 3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV 2014 and 4,016 by UBS Oncology. (F5) Immediately exercisable. |